References
- Rudwaleit M, Landewe R, Sieper J. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;375:1302–1303.
- van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991.
- Opris-Belinski D, Erdes SF, Grazio S, et al. Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries. Drugs Context. 2018;7:1.
- Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.
- Shim MR. Efficacy of TNF inhibitors in advance ankylosing spondylitis with total spinal fusion: case report and review of literature. Open Access Rheumatol. 2019;11:173–177.
- Kondo N, Yamamoto N, Watanabe K, et al. Bone histomorphometric findings in ankylosing spondylitis: a case report. J Bone Biol Osteoporosis. 2018;4:132–137.
- Mori K, Kasahara T, Mimura T, et al. Prevalence, distribution, and morphology of thoracic ossification of the yellow ligament in Japanese: results of CT-based cross-sectional study. Spine (Phila Pa 1976). 2013;38:E1216–1222.
- Fukui M, Chiba M, Kawakami S, et al. JOA Back Pain Evaluation Questionnaire (JOABPEQ)/JOA Cervical Myelopathy Evaluation Questionnaire (JOACMEQ). The report on the development of revised versions. April 16, 2007. The Subcommittee of the Clinical Outcome Committee of the Japanese Orthopaedic Association on Low Back Pain and Cervical Myelopathy Evaluation. J Orthop Sci. 2009;14:348–365.
- Rehman MT, Hoyland JA, Denton J, et al. Age related histomorphometric changes in bone in normal British men and women. J Clin Pathol. 1994;47:529–534.
- Cheung PP, Tymms KE, Wilson BJ, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Int Med J. 2008;38:396–401.
- Rudwaleit M, Olivieri I, Boki KA, et al. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford). 2008;48:551–557.
- Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late ankylosing spondylitis. Am J Med. 1997;103:233–241.
- Szejnfeld VL, Monier-Faugere MC, Bognar BJ, et al. Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. J Rheumatol. 1997;24:683–688.
- Orsolini G, Adami G, Rossini M, et al. Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Clin Rheumatol. 2018;37:3093–3098.
- Kocygit BF, Akyol A. Vitamin D levels in patients with ankylosing spondylitis: Is it related to disease activity? Pak J Med Sci. 2018;34:1209–1214.
- Pascal-Mousselard H, Smadja D, Cabre P, et al. Ossification of the ligamenta flava with severe myelopathy in a black patient. Spine. 1998;23:1607–1608.
- Niu CC, Lin SS, Yuan LJ, et al. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. BMC Musculoskelet Disord . 2017;18:61.
- Veerappan SG, Healy M, Walsh BJ, et al. Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn’s disease. Dig Dis Sci. 2015;60:2119–2129.